Oppenheimer Reaffirms “Market Perform” Rating for Inspire Medical Systems (NYSE:INSP)

Inspire Medical Systems (NYSE:INSP)‘s stock had its “market perform” rating reiterated by investment analysts at Oppenheimer in a research report issued to clients and investors on Thursday,Benzinga reports.

Other analysts have also issued research reports about the company. Mizuho reduced their target price on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a report on Tuesday. Zacks Research cut Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 14th. Wells Fargo & Company decreased their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a report on Tuesday. Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, Truist Financial dropped their target price on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating on the stock in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $85.00.

Inspire Medical Systems Stock Performance

Inspire Medical Systems stock opened at $44.28 on Thursday. Inspire Medical Systems has a fifty-two week low of $43.99 and a fifty-two week high of $161.88. The stock’s 50 day simple moving average is $56.01 and its two-hundred day simple moving average is $78.97. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 9.86, a PEG ratio of 4.78 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.38. The company had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. Inspire Medical Systems’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the business earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts predict that Inspire Medical Systems will post 0.9 earnings per share for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

A number of hedge funds have recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in Inspire Medical Systems by 16.0% during the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after buying an additional 4,528 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Inspire Medical Systems during the first quarter worth $524,000. Goldman Sachs Group Inc. increased its position in Inspire Medical Systems by 57.9% during the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after acquiring an additional 18,857 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Inspire Medical Systems by 3.8% in the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after acquiring an additional 577 shares during the period. Finally, Jump Financial LLC purchased a new stake in shares of Inspire Medical Systems in the second quarter valued at $931,000. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.